Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06725758 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours(TEADES) | recruiting | Phase 1 / Phase 2 | 315 | Orion Corporation, Orion PharmaINDUSTRY | 6 | May 8, 2026 | clinicaltrials |
| NCT07380386 | SKB105 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 256 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 |
| clinicaltrials |
| NCT06761417 | A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults | recruiting | Phase 2 | 49 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06926751 | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors | recruiting | Phase 2 | 132 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07043894 | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients | recruiting | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05985161 | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06819735 | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors(DOMISOL) | recruiting | Phase 1 / Phase 2 | 125 | Domain Therapeutics Australia Pty LtdINDUSTRY | 3 | May 6, 2026 | clinicaltrials |
| NCT06214143 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 68 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06416007 | Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors | recruiting | Phase 2 | 37 | University of CincinnatiOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07298772 | A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07300943 | Study in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 306 | Callio TherapeuticsINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT07058948 | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors(SFRT-IM-P2) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556276 | Study of CMTS1215 Injection in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05451602 | HEC169096 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 456 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06010342 | A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | recruiting | Phase 2 | 60 | Teligene USINDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07258121 | Study of ZGGS34 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03810339 | Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04879121 | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07290088 | Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients(PRL3-zumab) | recruiting | Phase 2 / Phase 3 | 52 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05120596 | First in Human Study of T3P-Y058-739 (T3P) | recruiting | Phase 1 / Phase 2 | 100 | T3 Pharmaceuticals AGINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05222620 | SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial | recruiting | Phase 2 | 90 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | Toray Industries, IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07326488 | A Study of MHB009C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07192107 | A Study of MHB042C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06911827 | A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 149 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05785741 | A Study of DB-1310 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,000 | DualityBio Inc.INDUSTRY | 2 | Apr 6, 2026 | clinicaltrials |
| NCT06306638 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction | recruiting | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07446153 | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects | recruiting | Phase 1 / Phase 2 | 282 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05773820 | A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Wigen Biomedicine Technology (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR) | recruiting | Phase 2 | 720 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03667170 | KN035 for dMMR/MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 200 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04891198 | ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 126 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07222969 | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 146 | Vibrant Sciences LimitedINDUSTRY | 2 | Mar 23, 2026 | clinicaltrials |
| NCT07032077 | A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors | recruiting | Phase 2 | 100 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07229638 | A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05101070 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors(aCCeleR8-001) | recruiting | Phase 1 / Phase 2 | 282 | ShionogiINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 87 | AkesoINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2026source: clinicaltrials